2.4 MG DOSE OF SEMAGLUTIDE, CURRENTLY INDICATED ONLY FOR PEOPLE WITH OBESITY, REDUCES THE RISK OF TYPE 2 DIABETES FOR PEOPLE WITH OBESITY.
New research presented by Dr. Timothy Garvey, professor of medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham, and others suggest that a 2.4mg dose of semaglutide, currently sold as Wegovy and indicated only for people with obesity, reduces the risk of type 2 diabetes for people with obesity.
Garvey, the lead investigator who presented the findings along with Dr. Jason Brett, executive director at Novo Nordisk, said, “Obesity is one of the main drivers associated with type 2 diabetes.”
This study, which used a model to predict risk for type 2 diabetes, focused on how treatment with semaglutide, a glucose-lowering and anti-obesity medication, affected the risk for type 2 diabetes. The results indicated an approximate reduction of 60% in the 10-year risk of developing type 2 diabetes after treatment with once-weekly semaglutide for 68 weeks.
Importantly, they found a significant risk reduction for people in the study who had prediabetes and were at risk for type 2 diabetes.
Garvey specified that the model incorporates “quantitative data readily available to clinicians and is highly predictive of who is going to get type 2 diabetes.” This data includes sex, age, race, BMI, blood pressure, blood glucose, triglycerides, and high-density lipoprotein (HDL) cholesterol.
|
Absolute 10-year T2D risk scores in all participants |
||
|
Week 0 |
Week 68 |
|
|
Semaglutide 2.4mg |
18.2 |
7.5 |
|
Placebo |
17.8 |
15.6 |
Garvey said that although extensive data exists on the weight loss potential from semaglutide 2.4mg, “there has not been a study done to look at diabetes prevention [until now].”
When comparing participants with and without prediabetes, both experienced reductions in risk scores for type 2 diabetes but those with prediabetes had a higher risk, so they had a greater overall reduction in risk based on the model.
With a tool like this, you could identify those most at risk for type 2 diabetes and bring more aggressive therapy to them.“Two-thirds of America are overweight or have obesity,” Garvey said. “With a tool like this, you could identify those most at risk for type 2 diabetes and bring more aggressive therapy to them.”
From www.diatribe.org
Nyhetsinfo
www red DiabetologNytt